CR7444A - Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativos - Google Patents
Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativosInfo
- Publication number
- CR7444A CR7444A CR7444A CR7444A CR7444A CR 7444 A CR7444 A CR 7444A CR 7444 A CR7444 A CR 7444A CR 7444 A CR7444 A CR 7444A CR 7444 A CR7444 A CR 7444A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- epotilones
- diseases associated
- proliferative processes
- cerebral diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Uso de una epotilona que presenta un coeficiente de distribucion promedio entre plasma y cerebro que comprende entre 0,3 y 1,5 en el ensayo de inyeccion de bolo intravenoso en raton, en la preparacion de un medicameto para el tratamiento de una enfermedad cerebral asociada con proesosos proliferativos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02004745A EP1340498A1 (en) | 2002-03-01 | 2002-03-01 | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
Publications (1)
Publication Number | Publication Date |
---|---|
CR7444A true CR7444A (es) | 2005-10-05 |
Family
ID=27675676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR7444A CR7444A (es) | 2002-03-01 | 2004-09-01 | Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativos |
Country Status (23)
Country | Link |
---|---|
US (1) | US20040019088A1 (es) |
EP (2) | EP1340498A1 (es) |
JP (1) | JP2005525360A (es) |
KR (1) | KR20040095244A (es) |
CN (1) | CN100473381C (es) |
AR (1) | AR038712A1 (es) |
AU (1) | AU2003215618B2 (es) |
BR (1) | BR0308154A (es) |
CA (1) | CA2477403A1 (es) |
CR (1) | CR7444A (es) |
EC (1) | ECSP045340A (es) |
HK (1) | HK1079998A1 (es) |
HR (1) | HRP20040892A2 (es) |
IL (1) | IL163752A0 (es) |
MX (1) | MXPA04008450A (es) |
NO (1) | NO20044175L (es) |
NZ (1) | NZ546617A (es) |
PL (1) | PL370768A1 (es) |
RU (1) | RU2351330C2 (es) |
UA (1) | UA83798C2 (es) |
WO (1) | WO2003074053A1 (es) |
YU (1) | YU76404A (es) |
ZA (1) | ZA200407905B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
IL134419A0 (en) * | 1997-08-09 | 2001-04-30 | Schering Ag | Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same |
PL350190A1 (en) * | 1999-02-11 | 2002-11-18 | Schering Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
WO2004018478A2 (en) | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DE10331004A1 (de) * | 2003-07-03 | 2005-02-24 | Schering Ag | Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten |
EP1559447A1 (en) * | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
EP1700596A1 (en) * | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
DE102007016046A1 (de) | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
BRPI0911482A2 (pt) * | 2008-04-24 | 2017-08-29 | Bristol Myers Squibb Co | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | ポリペプチドの酵素的結合 |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100400620B1 (ko) * | 1995-06-09 | 2004-02-18 | 노파르티스 아게 | 라파마이신유도체 |
US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
SK285969B6 (sk) * | 1997-02-18 | 2007-12-06 | Canji, Inc. | Prípravky na liečenie cicavčích nádorových alebo hyperproliferatívnych buniek |
GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
IL134419A0 (en) * | 1997-08-09 | 2001-04-30 | Schering Ag | Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same |
CA2311929A1 (en) * | 1997-12-04 | 1999-06-10 | Bristol-Myers Squibb Company | A process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
AU4775299A (en) * | 1998-06-22 | 2000-01-10 | Nicolaou, Kyriacos Costa | Desmethyl epothilones |
US6610736B1 (en) * | 1999-02-18 | 2003-08-26 | Schering Ag | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
PE20010116A1 (es) * | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
AU775373B2 (en) * | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
DE10020517A1 (de) * | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
US20020045609A1 (en) * | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
GB0013643D0 (en) * | 2000-05-31 | 2000-07-26 | Unilever Plc | Targeted moieties for use in bleach catalysts |
WO2002098868A1 (en) * | 2001-06-01 | 2002-12-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
-
2002
- 2002-03-01 EP EP02004745A patent/EP1340498A1/en not_active Withdrawn
-
2003
- 2003-02-28 CA CA002477403A patent/CA2477403A1/en not_active Abandoned
- 2003-02-28 AU AU2003215618A patent/AU2003215618B2/en not_active Expired - Fee Related
- 2003-02-28 PL PL03370768A patent/PL370768A1/xx not_active Application Discontinuation
- 2003-02-28 YU YU76404A patent/YU76404A/sh unknown
- 2003-02-28 JP JP2003572570A patent/JP2005525360A/ja active Pending
- 2003-02-28 WO PCT/EP2003/002085 patent/WO2003074053A1/en active Application Filing
- 2003-02-28 MX MXPA04008450A patent/MXPA04008450A/es not_active Application Discontinuation
- 2003-02-28 IL IL16375203A patent/IL163752A0/xx unknown
- 2003-02-28 UA UA20040907817A patent/UA83798C2/ru unknown
- 2003-02-28 RU RU2004129325/15A patent/RU2351330C2/ru active
- 2003-02-28 CN CNB038097613A patent/CN100473381C/zh not_active Expired - Fee Related
- 2003-02-28 EP EP03743360A patent/EP1480643A1/en not_active Withdrawn
- 2003-02-28 KR KR10-2004-7013549A patent/KR20040095244A/ko not_active Application Discontinuation
- 2003-02-28 NZ NZ546617A patent/NZ546617A/en unknown
- 2003-02-28 US US10/375,043 patent/US20040019088A1/en not_active Abandoned
- 2003-02-28 BR BR0308154-0A patent/BR0308154A/pt not_active Withdrawn
- 2003-03-03 AR ARP030100696A patent/AR038712A1/es unknown
-
2004
- 2004-09-01 CR CR7444A patent/CR7444A/es not_active Application Discontinuation
- 2004-09-28 HR HRP20040892 patent/HRP20040892A2/hr not_active Application Discontinuation
- 2004-09-30 NO NO20044175A patent/NO20044175L/no not_active Application Discontinuation
- 2004-09-30 EC EC2004005340A patent/ECSP045340A/es unknown
- 2004-09-30 ZA ZA200407905A patent/ZA200407905B/en unknown
-
2006
- 2006-01-04 HK HK06100157.3A patent/HK1079998A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NZ546617A (en) | 2007-12-21 |
BR0308154A (pt) | 2005-01-04 |
MXPA04008450A (es) | 2005-07-13 |
JP2005525360A (ja) | 2005-08-25 |
AU2003215618B2 (en) | 2009-06-04 |
PL370768A1 (en) | 2005-05-30 |
YU76404A (sh) | 2006-08-17 |
UA83798C2 (ru) | 2008-08-26 |
CN1649587A (zh) | 2005-08-03 |
KR20040095244A (ko) | 2004-11-12 |
EP1340498A1 (en) | 2003-09-03 |
US20040019088A1 (en) | 2004-01-29 |
AR038712A1 (es) | 2005-01-26 |
ECSP045340A (es) | 2004-11-26 |
IL163752A0 (en) | 2005-12-18 |
HRP20040892A2 (en) | 2004-12-31 |
HK1079998A1 (zh) | 2006-04-21 |
CN100473381C (zh) | 2009-04-01 |
ZA200407905B (en) | 2006-04-26 |
AU2003215618A1 (en) | 2003-09-16 |
CA2477403A1 (en) | 2003-09-12 |
RU2004129325A (ru) | 2005-07-10 |
WO2003074053A1 (en) | 2003-09-12 |
RU2351330C2 (ru) | 2009-04-10 |
EP1480643A1 (en) | 2004-12-01 |
NO20044175L (no) | 2004-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR7444A (es) | Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativos | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
UY31205A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
BRPI0911482A2 (pt) | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer | |
BG105575A (en) | Method and agent for the treatment of cerebral ischaemia | |
AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
ES2422286T3 (es) | Uso de apamina para tratar la enfermedad de Parkinson | |
WO2006012521A3 (en) | Treatment for ocular disease | |
CR9200A (es) | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos | |
D'Orazio et al. | 44th annual meeting of the American Society of Hematology. December 7-10, 2002: Philadelphia, Pennsylvania. Short-course chemotherapy without radiation therapy could be sufficient for elderly patients with localized aggressive non-Hodgkin's lymphoma | |
AR027152A1 (es) | Composicion farmaceutica para el tratamiento de la enfermedad cerebrovascular cognitiva. | |
UY27083A1 (es) | Composición farmacéutica para el tratamiento de la enfermedad cerebrovascular cognoscitiva |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC90 | Application suspended |